Advanced colon cancer is a growing cause of cancer-related death among young American men, particularly when it spreads to the liver. Liver metastases are highly resistant to current immunotherapies and often recur even after surgery, creating a critical need for new treatment strategies.
A recent study identified a novel dual-immunotherapy approach that reprograms the liver tumor microenvironment to enhance immune response. The therapy combines overexpression of the signaling protein LIGHT (TNFSF14), which stimulates immune cell activity, with an anti-CTLA-4 antibody that blocks a checkpoint receptor suppressing T-cell function. Together, these therapies promote robust immune infiltration and activation within liver tumors.
In preclinical models, this combination not only eradicated many tumors but also established long-term immune memory, enabling the immune system to recognize and attack recurring cancer cells. Researchers are now exploring targeted delivery systems to the liver, aiming to translate this promising approach into clinical trials for patients with metastatic colorectal cancer.